Lv2
146 积分 2022-04-20 加入
Clinical Impacts of Immunogenicity in Approved Antibody Drugs in Japan: A Quantitative Evaluation of Pharmacokinetics, Efficacy, and Safety Outcomes
6天前
已完结
Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins
1个月前
已完结
New insights into antibody structure with implications for specificity, variable region restriction and isotype choice
1个月前
已完结
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
2个月前
已完结
The global burden of inflammatory bowel disease: from 2025 to 2045
2个月前
已完结
Role of thymic stromal lymphopoietin in allergy and beyond
2个月前
已完结
Ulcerative colitis
2个月前
已完结
Expression, Localization, and Functional Activity of TL1A, a Novel Th1-Polarizing Cytokine in Inflammatory Bowel Disease
2个月前
已完结
Interleukin-23 p19 and Interleukin-12 p40, Head-to-Head, against Gut Inflammation
2个月前
已完结
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
2个月前
已完结
皖公网安备34019202002308
